Specialty Pharmacy

HIV non-disclosure not found to have an adverse impact on depression or anxiety symptoms.

Risk factor may serve as a future drug target for ulcerative colitis.

Availability of new therapies and cost concerns create barriers for cancer patients.

Daniel P. Kus, BS Pharm, RPh, discusses how specialty pharmacies can help patients manage out-of-pocket drug spending.

Findings may lead to increased survival in patients with glioblastoma.

PHLDB3 inhibits the p53 protein to promote tumor growth.

Study estimates 27% of men avoided an unnecessary biopsy for prostate cancer when given an MRI scan first.

Top news of the day from across the health care landscape.

Dalfampridine extended-release tablets deemed bioequivalent of Amprya.

Specialty pharmacy squares off with pharmacy benefit manager over contractual dispute.

PGAM1 inhibitors sensitize tumors to lynparza (Olaparib) treatment.

Statins degrade mutated p53 proteins, offering future cancer treatment.

Poor long-term survival rates for pediatric patients with acute megakaryoblastic leukemia.

New index more precisely determines the probability of reducing liver fat during lifestyle interventions.

The microbiome and inflammatory signature differs in patients with type 1 diabetes.

Top news of the day from across the health care landscape.

Conflicting evidence surrounds the association between multiple sclerosis and uveitis.

Top news of the week in oncology and cancer drug development.

Most of the Ebola-related deaths in West Africa could have been prevented, experts say.

Diabetes-related outcomes significantly differ by state and insurance type.

Increased use of biosimilars could create sustainable care for multiple chronic diseases.

Top articles of the week from Specialty Pharmacy Times.

The new test service helps physicians assess patient’s responses to antiretroviral therapy for HBV.

Cancer cells learn to cope with large scale DNA changes.

Top news of the day from across the health care landscape.

Pharmacists continue to rank big in lists that highlight the profession’s value.

Dan Steiber, RPh, to expand responsibilities to include overseeing all strategic business services for Specialty Pharmacy Times.

Specialty marketplace continues to thrive going forward.